Results 161 to 170 of about 92,781 (302)

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

What Happens When Undergraduate Biology Students Meet with Professional Scientists to Discuss Research? An Exploratory Investigation into Scientific Discourse, Motivation, and Sense of Belonging. [PDF]

CBE Life Sci Educ
Machrone A, Duenas M, Acosta A, Alvarez R, Bruce-Opris H, Castellano R, Chatzikyriakidou K, Concepcion K, Colon J, Hawks S, Knekta E, Mardini V, Moralejo L, Mousavi S, Duarte LN, Perez A, Russoniello E, McCartney M.   +17 more
europepmc   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Differential patterns in comparative education discourse

, 2004
This dissertation study argues that 'policy advice formation', as a discourse development, is a differentiated hybrid resultant from merger between comparative education and policy studies disciplines.
Coursey, Donna Annetta
core  

Terms of debate: Consensus definitions to guide the scientific discourse on visual distraction. [PDF]

Atten Percept Psychophys
Liesefeld HR, Lamy D, Gaspelin N, Geng JJ, Kerzel D, Schall JD, Allen HA, Anderson BA, Boettcher S, Busch NA, Carlisle NB, Colonius H, Draschkow D, Egeth H, Leber AB, Müller HJ, Röer JP, Schubö A, Slagter HA, Theeuwes J, Wolfe J.   +20 more
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

For a Postmedial Image: The Challenge of Enunciation for the Digital Practices of the Contemporary Image

Signata
This paper aims to propose some suggestions on what role semiotic analysis of the visual can take in the postmediality environment. Taking a case study from the field of scientific research on biodiversity, that is, the INaturalist platform, what we wish
Paolo Pinos
doaj  

Semi-supervised learning of causal relations in biomedical scientific discourse. [PDF]

Biomed Eng Online, 2014
Mihăilă C, Ananiadou S.
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

PRAGMATICS OF SCIENTIFIC DISCOURSE [PDF]

Novosibirsk State Pedagogical University Bulletin, 2015
openaire   +1 more source